Search

Roche Holding AG

Gesloten

SectorGezondheidszorg

293.8 -2.59

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

291

Max

301.6

Belangrijke statistieken

By Trading Economics

Inkomsten

6.3B

Verkoop

31B

K/W

Sectorgemiddelde

29.748

63.778

Dividendrendement

3.1

Winstmarge

20.347

Werknemers

103,249

EBITDA

11B

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.10%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

233B

Vorige openingsprijs

296.39

Vorige sluitingsprijs

293.8

Nieuwssentiment

By Acuity

18%

82%

176 / 386 Rangschikking in Healthcare

Roche Holding AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mrt 2025, 09:23 UTC

Belangrijke Marktbewegers

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30 jan 2025, 09:36 UTC

Winsten

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 jan 2025, 06:32 UTC

Winsten

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

3 apr 2025, 08:41 UTC

Marktinformatie

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 apr 2025, 07:51 UTC

Marktinformatie

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mrt 2025, 09:31 UTC

Populaire aandelen

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13 mrt 2025, 07:46 UTC

Marktinformatie

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12 mrt 2025, 16:34 UTC

Top Nieuws

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mrt 2025, 08:51 UTC

Marktinformatie

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12 mrt 2025, 08:18 UTC

Marktinformatie

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13 feb 2025, 11:43 UTC

Marktinformatie

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 jan 2025, 07:56 UTC

Marktinformatie
Winsten

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 jan 2025, 06:04 UTC

Winsten

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30 jan 2025, 06:04 UTC

Winsten

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30 jan 2025, 06:04 UTC

Winsten

Roche Issues 2025 View

30 jan 2025, 06:03 UTC

Winsten

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30 jan 2025, 06:03 UTC

Winsten

Roche 2024 Core Operating Profit CHF20.82B

30 jan 2025, 06:03 UTC

Winsten

Roche 2024 Net Pft CHF9.19B

30 jan 2025, 06:02 UTC

Winsten

Analysts Saw 2024 Core EPS at CHF18.59

30 jan 2025, 06:02 UTC

Winsten

Roche 2024 Core EPS CHF18.80

30 jan 2025, 06:02 UTC

Winsten

Roche 2024 Sales EUR60.50B

30 jan 2025, 06:02 UTC

Winsten

Analysts Saw Roche 2024 Revenue at CHF60.41B

30 jan 2025, 06:01 UTC

Winsten

Roche 2024 Sales CHFB

28 jan 2025, 10:30 UTC

Top Nieuws

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28 jan 2025, 07:24 UTC

Marktinformatie

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15 jan 2025, 10:22 UTC

Marktinformatie

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8 jan 2025, 06:15 UTC

Acquisities, Fusies, Overnames

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8 jan 2025, 06:12 UTC

Acquisities, Fusies, Overnames

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16 dec 2024, 22:03 UTC

Top Nieuws

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 dec 2024, 16:36 UTC

Marktinformatie

Swiss Equities an Overweight Pick Next Year -- Market Talk

Roche Holding AG Prognose

Sentiment

By Acuity

176 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.